Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Kanavos

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Journal of Health Services Research & Policy|July 1, 1999
International comparisons of health care expenditures: what we know and what we do not knowP Kanavos, E Mossialos
BMJ (Clinical Research Ed.)|April 30, 1999
Cross border health care in EuropeP Kanavos, M McKee, T Richards
International Journal of Technology Assessment in Health Care|January 13, 2001
Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United KingdomP Kanavos, P Trueman, A Bosilevac
Social Science & Medicine (1982)|October 19, 2023
A structured methodology for essential medicines lists and health emergency stockpiles: Experience with the Emergency Medicines Buffer Stock in the United KingdomA Angelis, G Montibeller, P Kanavos
Orphanet Journal of Rare Diseases|September 6, 2022
Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life studyA Angelis, J E Mellerio, P Kanavos
Pharmacoeconomics|March 8, 1997
Will managed care work in Europe?E Mossialos, P Kanavos, B Abel-Smith
Ecancermedicalscience|January 26, 2012
The role of funding and policies on innovation in cancer drug developmentP Kanavos, R Sullivan, G Lewison, et al.
Health Policy (Amsterdam, Netherlands)|December 12, 2018
Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?J López-Bastida, J M Ramos-Goñi, I Aranda-Reneo, et al.
Social Science & Medicine (1982)|December 25, 2019
Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value FrameworkA Angelis, M Linch, G Montibeller, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Implications Of External Price Referencing of Pharmaceuticals in Middle East CountriesZ Kalo, I Alabbadi, Ahdab O G Al, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Journal of Health Services Research & Policy|July 1, 1999
International comparisons of health care expenditures: what we know and what we do not knowP Kanavos, E Mossialos
BMJ (Clinical Research Ed.)|April 30, 1999
Cross border health care in EuropeP Kanavos, M McKee, T Richards
International Journal of Technology Assessment in Health Care|January 13, 2001
Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United KingdomP Kanavos, P Trueman, A Bosilevac
Social Science & Medicine (1982)|October 19, 2023
A structured methodology for essential medicines lists and health emergency stockpiles: Experience with the Emergency Medicines Buffer Stock in the United KingdomA Angelis, G Montibeller, P Kanavos
Orphanet Journal of Rare Diseases|September 6, 2022
Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life studyA Angelis, J E Mellerio, P Kanavos
Pharmacoeconomics|March 8, 1997
Will managed care work in Europe?E Mossialos, P Kanavos, B Abel-Smith
Ecancermedicalscience|January 26, 2012
The role of funding and policies on innovation in cancer drug developmentP Kanavos, R Sullivan, G Lewison, et al.
Health Policy (Amsterdam, Netherlands)|December 12, 2018
Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?J López-Bastida, J M Ramos-Goñi, I Aranda-Reneo, et al.
Social Science & Medicine (1982)|December 25, 2019
Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value FrameworkA Angelis, M Linch, G Montibeller, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Implications Of External Price Referencing of Pharmaceuticals in Middle East CountriesZ Kalo, I Alabbadi, Ahdab O G Al, et al.
Pageof 3